Next Article in Journal
3D Printing of Drug-Loaded Thermoplastic Polyurethane Meshes: A Potential Material for Soft Tissue Reinforcement in Vaginal Surgery
Previous Article in Journal
Energy Transfer in Vials Nested in a Rack System During Lyophilization
Previous Article in Special Issue
Amphiphilic Polypeptides for VEGF siRNA Delivery into Retinal Epithelial Cells
Open AccessReview

Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?

Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(1), 62; https://doi.org/10.3390/pharmaceutics12010062
Received: 19 November 2019 / Revised: 13 December 2019 / Accepted: 28 December 2019 / Published: 13 January 2020
(This article belongs to the Special Issue Drug Delivery across Biological Barriers)
The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood–brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells. View Full-Text
Keywords: adsorptive-mediated transcytosis; antibody fragments; blood–brain barrier; brain metastases; monoclonal antibodies; peptide shuttles adsorptive-mediated transcytosis; antibody fragments; blood–brain barrier; brain metastases; monoclonal antibodies; peptide shuttles
Show Figures

Graphical abstract

MDPI and ACS Style

Cavaco, M.; Gaspar, D.; ARB Castanho, M.; Neves, V. Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Pharmaceutics 2020, 12, 62.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop